top of page

MBK-103, our lead candidate

An ADC targeting FOLR1 (or FRα) based on PSARLink™ platform

MBK-103 consists of


an Fc-silent humanized IgG1 monoclonal antibody, that binds selectively to FRα


a polysarcosine hydrophobicity masking entity that allows for a high drug-antibody-ratio (DAR) of 8, while improving the pharmacokinetics and tolerability of the drug


a proprietary dipeptide cleavable unit


exatecan, a potent topoisomerase I inhibitor as the payload

FRα is a clinically validated target overexpressed in numerous solid tumors with high unmet medical need

Ovarian, non-small cell lung, colorectal and triple-negative breast cancers are among the indications with the highest frequency of FRα-positive patients.
First-in-human studies are to start in 2024.
Mablink has generated in vivo data in animal models that confirm the proof-of-concept results published on the proprietary PSARLink™ platform : improved tolerability with a lower risk of off-target toxicity thanks to an enhanced hydrophilicity and plasma stability, and higher anti-tumor efficacy, with a longer half-life, similar to the unconjugated antibody, and an increased drug exposure.

These data were first presented at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Publications and presentations:

bottom of page